Abstract: The compositions and methods of the invention provide compositions and methods for preferential targeting of tissues to delivery therapeutic or diagnostic agents. For example, such compounds are useful in the treatment of joint disorders those affecting articulating joints, e.g., injury-induced osteoarthritis as well as autoimmune diseases affecting joint tissue such as rheumatoid arthritis.

Abstract: Provided are a pharmaceutical composition of a substituted pyrazolo[1,5-a]pyrimidine macrocyclic compound and the use thereof. The pyrazolo[1,5-a]pyrimidine macrocyclic compound is a compound as shown in formula (Aa), or a pharmaceutically acceptable salt, a prodrug, a hydrate or a solvate, a crystal form, a stereoisomer or an isotopic variant thereof. The compound of the present invention is an inhibitor of the Trk kinase, and can be used for treating pain, cancers, inflammation, neurodegenerative diseases and certain infectious diseases.

Abstract: The present invention relates to a composition which is for preventing or treating caffeine abuse and includes evodiamine or Evodia officinalis extract. More specifically, the present invention relates to a pharmaceutical composition which has an effect of preventing or alleviating somnipathy and central nervous system excitation caused by caffeine. In addition, the present invention relates to a caffeine abuse treatment method and a health functional food composition including Evodia officinalis extract or evodiamine.

Abstract: The field of the DISCLOSURE lies in active materials for organic image sensors. The present disclosure relates to naphthalene diimide-based molecules and naphthalene diimide dimer-based molecules. The present disclosure relates to transparent N materials and/or to transparent P materials including the molecule(s) according to the present disclosure and their use in absorption layer(s), photoelectric conversion layer(s) and/or an organic image sensor and methods for their synthesis. The present disclosure also relates to photoelectric conversion layer(s) including an active material according to the present disclosure, to a device, including active material(s) according to the present disclosure or photoelectric conversion layer(s) according to the present disclosure. Moreover, the present disclosure relates to an organic image sensor including photoelectric conversion layer(s) according to the present disclosure.

Abstract: The present invention relates to chlorinated naphthalenetetracarboxylic acid derivatives, preparation thereof and use thereof as charge transport materials, exciton transport materials or emitter materials.

Abstract: The present invention provides the compounds of formulae (3) and (1) wherein n is 0 or 1, R13 and R14 are the same or different and are selected from the group consisting of NHR310, NR311R312, OR313, SR314 and R315, or R13 and R14 together are selected from the group consisting of (a), (b) and (c), and X is CI, Br of I, and a process for the preparation of compounds of formula (3) comprising the compounds of formula (1) as key intermediates.

Abstract: Disclosed is a wavelength-conversion material, and methods for its use, that includes an organic fluorescent dye and a polymeric matrix, wherein the organic fluorescent dye is solubilized in the polymeric matrix, and wherein the polymeric matrix is capable of absorbing light comprising a wavelength of 500 to 700 nm and emitting the absorbed light at a wavelength of greater than 550 to 800 nm.

Abstract: The present invention relates to compounds of the formula (1) and to the use thereof in organic electronic devices, and to organic electronic devices which comprise compounds of the formula (1), preferably as hole-transport materials and/or as emitting materials.

Abstract: Luminescent labels based on aromatic and heterocyclic compounds, including reactive intermediates used to synthesize these compounds, and methods of synthesizing and using these reporter compounds. These labels combine high photostabilities, large Stokes' shifts and contain a pyrimidinium moiety as a water-soluble group. These luminescent compounds relate generally to the following structure: The methods relate generally to the synthesis and/or use of reporter compounds for fluorescence lifetime or fluorescence polarization based applications.

Abstract: Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Abstract: An organic electroluminescence device and a material for producing the organic electroluminescence device. The organic electroluminescence device includes an organic thin film layer between a cathode and an anode, the organic thin film layer including one or more layers, in which the organic thin film layer includes one or more light emitting layers and at least one of the light emitting layers includes a phosphorescent material and a host material. The host material has an essential structure in which a naphthalene ring is bonded to a fluorene skeleton, dibenzofuran skeleton, or dibenzothiophene skeleton. The organic electroluminescence device is a phosphorescent device having high efficiency and long lifetime.

Abstract: Use of a precursor of an n-dopant for doping an organic semiconductive material, as a blocking layer, as a charge injection layer, as an electrode material, as a storage material or as a semiconductor material itself in electronic or optoelectronic components, the precursor being selected from the following formulae 1-3c:

Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.

Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.

Abstract: The present specification discloses honeybee repellents exhibiting repellent properties similar to 2-heptanone, compositions comprising such repellents, uses to repel a honeybee from a mammal, location, plant, structure treated of such repellents, and methods of treating a mammal, location, plant, structure by applying such repellents.

Abstract: The present invention provides a novel class of peptide nucleic acid derivatives, which show good cell penetration and strong binding affinity for nucleic acid.

Abstract: An organic electroluminescent element using a compound represented by the following general formula (I) emits dark blue light and has small changes in the chromaticity and in the driving voltage even after driving for a long period of time: wherein R1 to R6; Q1 and Q2; X1, X2, X3 and X4 are as defined herein.

Abstract: There is provided compounds of formula I, wherein R1, R2a, R2b, R2c, X, Y, Z, R3 and ring A/B have meanings given in the description, and pharmaceutically-acceptable esters, amides, solvates or salts thereof, which compounds are useful in the treatment of diseases in which inhibition of a protein or lipid kinase (e.g. PI3-K, particularly class I PI3K, PIM family kinase and/or mTOR) is desired and/or required, and particularly in the treatment of cancer. The invention also relates to combinations containing such compounds.

Abstract: Thiazole and thiophene compounds are disclosed having utility in treating inflammatory conditions, immunoinflammatory conditions, autoimmune diseases, and cancers. Methods for the synthesis of these compounds are also disclosed.

Abstract: A heterocyclic compound represented by Formula 1 below and an organic light-emitting device including the heterocyclic compound: wherein R1 to R12 are defined as in the specification.

Abstract: The present invention is directed to implants and the modification of the surface of implants using amino acid or polypeptide functionalized rosette nanotubes.

Abstract: Dendronic reporters are described which incorporate a high density of luminescent or non-luminescent dyes at periphery sites and a focal point group that is reactive, ionic or a conjugated substance. Such dendronic reporters are capable of sensing analytes, or are otherwise useful in luminescent assays. Additionally, methods of synthesis are described.

Abstract: The invention relates to compounds of the formula (I) in which Y1 and Y2 are each O or, respectively, NRa or NRb, where Ra and Rb are each H or organyl; Z1 to Z4 are each O or S; R11 to R14, R21 to R24 are each Cl, F; where 1 or 2 of the R11 to R14, R21 to R24 radicals may also be CN and/or 1 R11 to R14, R21 to R24 radical may be H; and where, when Y1 is NRa, Z1 or Z2 may also be NRc, where Ra and Rc together are a bridging X group having from 2 to 5 atoms; and where, when Y2 is NRb, Z3 or Z4 may also be NRd, where Rb and Rd together are a bridging X group having from 2 to 5 atoms; to a process for preparation thereof, and to their use as emitter materials, charge transport materials or exciton transport materials.

Abstract: Imaging agents of formulas (I)-(V) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formulas (I)-(V) capable of binding to tau proteins and ?-amyloid peptides are presented herein. The invention also relates to methods of imaging A? and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formulas (I)-(V) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders.

Abstract: The teachings provided herein generally relate to compositions comprising rutaecarpine derivatives that activates CYP1A2 through enzyme induction. The uses for such a derivative can include removing caffeine from a subject, improving sleep, treating insomnia, treating caffeine toxicity, treating caffeine addiction and withdrawal symptoms, and the like. Caffeine is just one example of a substrate that can be removed using the derivatives taught herein, and other examples, including theophylline, are provided herein.

Abstract: Provided are a nitrogen-containing aromatic compound useful for an organic electroluminescent device, and an organic electroluminescent device (organic EL device) that improves luminous efficiency of the device and sufficiently ensures driving stability of the device. The nitrogen-containing aromatic heterocyclic compound is represented by the following formula (1). The organic EL device includes an organic layer that contains the nitrogen-containing aromatic heterocyclic compound between an anode and a cathode laminated on a substrate. In the formula (1), a ring A represents an aromatic ring represented by the formula (1a) and fused with two adjacent rings, a ring B represents a heterocycle represented by the formula (1b) and fused with two adjacent rings, Y's each represent C—R or N, X's each represent N—Z, O, S, or Se, R represents hydrogen, an alkyl group, an aromatic group, or the like, and Z represents an alkyl group, an aromatic group, or the like.

Abstract: A tetraazaperopyrene compound of formula (I): wherein: R1, R2, R3, R4, R5, R6, R7, R8 at each occurrence, independently are selected from H, Cl and Br, with the proviso that at least one of R 1, R2, R3, R4, R5, R6, Wand R8 is Cl or Br, R9, R10, at each occurrence, independently are selected from H, a C1-30 alkyl group, a C1-30 haloalkyl group, a C6-14 aryl group, a heteroaryl group having 5 to 14 ringatoms, and a C7-20 arylalkyl group, wherein aryl, heteroaryl and arylalkyl can be optionally substituted with one or more halogen, C1-4 haloalkyl, —CN, —NO2, —CHO, —COOH, —CONH2, —CO(C1-14 alkyl), —COO(C1-14 alkyl), —CONHC(C1-14 alkyl) and —CON(C1-14 alkyl)2 groups.

Abstract: Provided herein are compounds of formula (I), pharmaceutical compositions comprising the compounds, and methods of use thereof The compounds provided herein modulate kinase activity, including PI3 kinase activity, and are useful for treating diseases and conditions associated with kinase activity, including diseases and conditions associated with PI3 kinase activity.

Abstract: The application relates to methods and systems for analysis of dissociation behavior of nucleic acids and identification of nucleic acids. In one aspect, methods and systems are disclosed for identifying a nucleic acid in a sample including an unknown nucleic acid and for detecting a single nucleotide polymorphism in a nucleic acid in a sample. Methods and systems are also disclosed for identification of a nucleic acid in a biological sample including at least one unknown nucleic acid by fitting denaturation data including measurements of a quantifiable physical change of the sample at a plurality of independent sample property points to a function to determine an intrinsic physical value and to obtain an estimated physical change function, and identifying the nucleic acid in the biological sample by comparing the intrinsic physical value for at least one unknown nucleic acid to an intrinsic physical value for a known nucleic acid.

Abstract: The tetracycline class of antibiotics has played a major role in the treatment of infectious diseases for the past 50 years. However, the increased use of the tetracyclines in human and veterinary medicine has led to resistance among many organisms previously susceptible to tetracycline antibiotics. The modular synthesis of tetracyclines and tetracycline analogs described provides an efficient and enantioselective route to a variety of tetracycline analogs and polycyclines previously inaccessible via earlier tetracycline syntheses and semi-synthetic methods. These analogs may be used as anti-microbial agents or anti-proliferative agents in the treatment of diseases of humans or other animals.

Abstract: A heterocyclic compound includes compounds represented by Formula 1 or Formula 2 below:

Abstract: The present invention relates to aromatic nitrogen heterocycles, and to electronic devices, in particular organic electroluminescent devices, which comprise these aromatic nitrogen heterocycles, in particular in a hole-injection layer and/or in a hole-transport layer and/or in a hole-blocking layer and/or in an electron-transport layer and/or in an emitting layer.

Abstract: A process for preparing colorants of the general formula (Ia), (Ib) or (Ic) or mixtures thereof, comprises reacting (a) tetracarboxylic acids or their functional derivatives with (b) at least one compound selected from i. aliphatic amines, ii. aromatic amines, iii. aliphatic diamines, iv. aromatic diamines, (c) optionally in the presence of further additives, (d) optionally in the presence of wetting agents in a mixing apparatus. These colorants are useful for coloration of macromolecular organic and inorganic materials of natural and synthetic origin.

Abstract: The present application relates to compounds and methods for treating pain, incontinence and other conditions.

Abstract: This document relates to compounds as well as methods and materials involved in modulating neurotransmitter reuptake. For example, compounds, methods for synthesizing compounds, and methods for inhibiting neurotransmitter reuptake are provided.

Abstract: Disclosed are small molecule inhibitors of the formula (I), which are useful in treating various diseases and conditions involving chymase.

Abstract: An activated carbon material for removing a contaminant from a liquid. The activated carbon material can be a plurality carbon grains that have a pore volume of approximately 0.1 milliliters per gram (mL/g) in the range of less than about 15 angstroms in width. The carbon grains can also have or contain a nitrogen-containing species having a concentration of more than 2 atomic percent nitrogen. A plurality of the carbon grains can be used to make a contactor that is operable to remove or reduce perchlorate having a concentration of 20 parts per billion (ppb) to less than 4 ppb from 4,500 bed volumes of water with the nitrogen-containing species leaching off of the carbon grains less than 0.1 mg/L. The activated carbon material can also be electrochemically regenerated.

Abstract: Processes for the preparation of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline, salts thereof, and the intermediates used in the process are described.

Abstract: The invention relates to compounds of the formula (I) in which Y1 and Y2 are each O or, respectively, NRa or NRb, where Ra and Rb are each H or organyl; Z1 to Z4 are each O or S; R11 to R14, R21 to R24 are each Cl, F; where 1 or 2 of the R11 to R14, R21 to R24 radicals may also be CN and/or 1 R11 to R14, R21 to R24 radical may be H; and where, when Y1 is NRa, Z1 or Z2 may also be NRc, where Ra and Rc together are a bridging X group having from 2 to 5 atoms; and where, when Y2 is NRb, Z3 or Z4 may also be NRd, where Rb and Rd together are a bridging X group having from 2 to 5 atoms; to a process for preparation thereof, and to their use as emitter materials, charge transport materials or exciton transport materials.

Abstract: Provided herein are macrocyclic serine protease inhibitor compounds, for example, of Formula Ia or Ib, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Abstract: The present invention discloses a gamboge acid cyclization analogs, their preparation methods and applications by semi-synthesis with the following structural formula I-III: Where ring A, ring B or/and ring C is 4-10 membered saturated or/and unsaturated aliphatic ring aliphatic heterocycle or aryl heterocycle. R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11 or/and R12 is, independently at each occurrence, optionally substituted substituent of glycosyl, multi-hydroxyl, amino acid, acyloxy, phosphoric acid oxy, sulfonyloxy, alkoxy, aryloxy, heterocyclic oxy, thiol, aliphatic or cyclic group containing oxygen, sulfur, nitrogen or phosphorus, one of the substituents or combinations thereof. The present invention has antitumor activity management, antiviral, antibacterial and antifungal activity management, as anti-tumor, anti-viral, immune, antibacterial and antifungal agents, with other known anti-tumor, anti-viral, immune, together with the application of antibacterial and antifungal.

Abstract: The teachings provided herein generally relate to compositions comprising rutaecarpine derivatives that activates CYP1A2 through enzyme induction. The uses for such a derivative can include removing caffeine from a subject, improving sleep, treating insomnia, treating caffeine toxicity, treating caffeine addiction and withdrawal symptoms, and the like. Caffeine is just one example of a substrate that can be removed using the derivatives taught herein, and other examples, including theophylline, are provided herein.

Abstract: The present invention provides compounds of Formula (I-IV): compositions containing the same, and methods of use thereof such as for the treatment of cancer.

Abstract: The invention relates to the use of a compound of the formula (I), or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for use in modulating an immune or inflammatory response: wherein: Z=O or S; n=1-3; R3=—CO2R8, —C(O)SR8, —C(O)NHR8, —C(S)OR8, —C(S)SR8, —C(S)NHR8, —C(NH)SR8 or —C(NH)NHR8, wherein R8 is —H or alkyl; R4=—H, —CH2R5 or —CH2CH2R5, wherein R5 independently has one of the meanings of R3; B=—NR2—, —CH2NR2—, —CH2CH2NR2—, —CH2CHR7— or —CH2O—, wherein R2 is H or a C1-3 alkyl, alkenyl or alkynyl group, and R7 is H or a C1-3 alkyl or alkoxy group; A=wherein R1=—NH2 or —OH, C and D are each, independently, a 5- or 6-membered, substituted or unsubstituted, aromatic or non-aromatic ring which may also contain one or more heteroatoms, and C is connected to group B in any available position.

Abstract: The invention is directed to methods and compositions for inhibiting caspase-independent apoptosis. In particular, methods and compositions for inhibiting Omi/HtrA2 activity, as well as method for identifying other inhibitors of Omi/HtrA2. Also disclosed are Omi/HtrA2 specific substrates and methods for identifying other substrates of Omi/HtrA2.

Abstract: Compounds effective in inhibiting replication of Hepatitis C virus (“HCV”) or other viruses are disclosed. This invention is also directed to compositions comprising such compounds, co-formulation or co-administration of such compounds with other anti-viral or therapeutic agents, processes and intermediates for the syntheses of such compounds, and methods of using such compounds for the treatment of HCV or other viral infections.

Abstract: The present invention relates to a dye of formula (I) where R1, R2, X, Y and t are each as defined in claim 1, to its preparation and to its use.

Abstract: The invention relates to novel heterocycles of formula (I) processes for their preparation and their use for preparing medicaments for the treatment or prophylaxis of disorders, especially of hyperproliferative disorders.

Abstract: The present invention relates to electronic devices, especially electroluminescent devices, comprising azapyrenes of formula (I), or formula (III), wherein Y1, Y2, Y3, Y4, X1, X2 and X3 are independently each other N, or CR4, with the proviso that at least one of the groups X1, X2 and X3 is a group CR4, R1 is hydrogen, F, —SiR100R101R102, or an organic substituent, R4 is hydrogen, F, —SiR100R101R102, or an organic substituent, or any of the substituents R1, R1? and R4, which are adjacent to each other, together form an aromatic, or heteroaromatic ring, or ring system, which can optionally be substituted, m is an integer of 1 to 6, and R100, R101 and R102 are independently of each other a C1-C8alkyl group, a C6-C24aryl group, or a C7-C12aralkyl group, which may optionally be substituted, and Q is a linking group; with the proviso that in the compound of formula (III) at least one of the substituents R1, or R4 is a group Q; especially as host for phosphorescent emitters, electron transporting materials, or emit

Abstract: A novel compound which is useful as an agent for treating and/or preventing emesis, vomiting and/or constipation. A compound represented by the formula (I): wherein R1 and R2 are each independently hydrogen, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted cycloalkyl, optionally substituted aryl etc., R3 is hydrogen, hydroxy, optionally substituted lower alkyl, optionally substituted lower alkenyl, optionally substituted lower alkynyl, optionally substituted lower alkoxy etc., R4 is hydrogen or lower alkyl, R5 is hydrogen, lower alkyl, cycloalkyl lower alkyl or lower alkenyl, or a pharmaceutically acceptably salt, or a solvate thereof is provided.